Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics — Investor Presentation (March 2014)

33 slides from Sorrento Therapeutics's investor presentation, Mar 20, 2014

  1. Slide 1: Next-Generation Cancer Therapeutics

    March 2014 Next-Generation Cancer Therapeutics Sorrento Therapeutics Exhibit 99.1

  2. Slide 2: Board of Directors and Management Team

    Board of Directors William S. Marth - Chairman Albany Molecular (President and CEO) Teva – Americas (former President and CEO) Mark Durand Watson, Teva – Americas (former CFO) Cam Gallagher Nerveda, LLC (Managing Director) Kim D. Janda, Ph.D. The Scripps Research Institute (Prof.) Henry Ji, Ph.D. So

  3. Slide 3: Next-Generation Cancer Therapeutics

    Next-Generation Cancer Therapeutics TUMOR Cynviloq Bioequivalence regulatory pathway Efficacy demonstrated US and EU rights G-MAB High-diversity human Ab library Lead mAb programs include PD-L1, PD-1, and CCR2 G-MAB targets toxin to cancer cell Proprietary toxins and linkers C-Lock and K-Lock conjug

  4. Slide 4: Pipeline: Cynviloq, G-MAB, ADC, RTX

    505(b)(2) Bioequivalence } PHASE 3 PHASE 2 PHASE 1 PRECLINICAL Multiple Commercialization & Partnership Opportunities * Abraxane orphan drug status (FDA approval, September 2013) INDICATION > TARGET Cynviloq G-MAB ADC RTX Oncology > PD - L1 Oncology/Inflammation > CCR2, CXCR3 Oncology > VEGFR2, c -

  5. Slide 5: Cynviloq: Lead Oncology Product Opportunity

    Registration Trial Lead Oncology Product Opportunity Cynviloq

  6. Slide 6: Cynviloq: Next Generation Paclitaxel Therapy

    Cynviloq: Next Generation Paclitaxel Therapy Mean size ~25 nm Cynviloq paclitaxel polymeric micelle Chemical polymer: Poly-lactide and polyethylene glycol diblock copolymer rd >300 mg/m (up to mg/m ) Mean size 130 nm Biological polymer: Donor-derived human serum albumin (HSA) nd mg/m Taxol ® paclita

  7. Slide 7: Equivalent PK in Mice

    Drug HL (h) T max (h) AUCinf (h*ng/mL) Vz (mL/kg) Cl (mL/h/kg) IV bolus at 30 mg/kg; n = 3 Equivalent PK in Mice Data on file Cynviloq Abraxane Abraxane 2.99 0.08 61561.33 2103.71 487.32 Cynviloq 2.83 0.08 58151.31 2103.58 515.90

  8. Slide 8: Comparable PK in Humans

    Abraxane data from: Nuhad K. Ibrahim, Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-free, Protein-stabilized, Nanoparticle Formulation of Paclitaxel. Clinical Cancer Research 2002;8:1038-44 Data from 2 separate studies (3 h infusion, mg/m dose, n=3) Comparable PK in Humans

  9. Slide 9: Bioequivalence = Efficient Pathway to Market

    Bioequivalence = Efficient Pathway to Market BE registration study in breast cancer patients (2014) - Duration = 12 months (including patient recruitment) - Direct trial cost ~$5M Abraxane (n = 50) Cynviloq (n = 50) Cynviloq Abraxane Cycle 1 Cycle 2 * Based on FDA “Draft Guidance on Paclitaxel” – Se

  10. Slide 10: Potential Cynviloq Advantages

    Cynviloq Abraxane Taxol Cynviloq Advantage Potential Cynviloq Advantages Maximum Tolerated Dose (mg/m ) >300 Potential for higher efficacy Rapid reconstitution: no foaming concerns Convenience for busy practices and pharmacies No donor-derived human serum albumin (HSA) No viral / prion concerns Conv

  11. Slide 11: Next Steps for Cynviloq

    Next Steps for Cynviloq BE study initiation: 1Q 2014 NDA filing: 2015 Product launch (MBC and NSCLC): 2016 sNDA planning for label expansion into pancreatic, bladder, and ovarian cancers NDA Filing FDA Approval BE Study LAUNCH

  12. Slide 12: RTX: Intractable Cancer Pain

    Intractable Cancer Pain Clinical Stage Pain Management Asset RTX

  13. Slide 13: Two Injection Sites = Two Products for Human Use

    Two Injection Sites = Two Products for Human Use Intratheca l (injection into the cerebrospinal fluid space) (injection into or nerve the ganglion) Intraganglionic

  14. Slide 14: RTX Ablates TRPV1-Positive Neurons

    RTX Ablates TRPV1-positive Neurons after Intrathecal Injection TRPV1 TRPV1 TRPV1 Fore limb TRPV1 positive Hind limb TRPV1 negative Adapted from Karai et al. 2004

  15. Slide 15: Open-Label Study in Companion Dogs

    Brown et al, 2005 n=18 n=18 n=8 n=5 n=4 Weeks ( p < 0.0001 for all time points) 100% response rate with single intrathecal injection 12 dogs reduced or discontinued analgesics Dogs passed away due to underlying osteosarcoma, not RTX treatment Permanent analgesic effect Personality intact Gait and mo

  16. Slide 16: Unilateral Effect Following Trigeminal Injection

    Unilateral Effect Following Trigeminal Injection Adapted from Tender et al. 2005 Left eye (blue) vs Right eye (red) Nociceptive neuron- mediated neurogenic inflammation (Evans blue)

  17. Slide 17: Next Steps for RTX Development

    Next Steps for RTX Development ~3 years for clinical development Filing for MUMS designation for osteosarcoma in dogs Intractable cancer pain clinical Phase 1/2 trial ( intrathecal injection ); n~40 patients Under Sorrento IND Phase 1/2 trial for osteosarcoma ( intraganglionic injection ); n~15 pati

  18. Slide 18: Antibodies + Proprietary Toxins: G-MAB & ADC

    Antibodies + Proprietary Toxins Immunotherapy Programs G-MAB & ADC

  19. Slide 19: G-MAB: Library of Therapeutic Antibodies

    Size of Target Antigen G-MAB: Library of Therapeutic Antibodies High Value Oncology Targets: Immune modulation: PD1 and PD-L1 Antibody Drug Conjugates: VEGFR2 and c-Met Proprietary technology: RNA amplification used for library generation Freedom-To-Operate Very high library diversity: 2.1 x 10 dist

  20. Slide 20: Anti-PD-L1 mAbs Exhibit Potent Activity

    Immune Modulation* Tumor Mouse Model** Competitor mAb Sorrento mAb Anti-PD-L1 mAbs Exhibit Potent Activity * mAbs @ 0.05 mg/mL ** xenograft model using H1975 human NSCLC cells; % inhibition relative to control mAb treatment *** p<0.05, mean tumor volumes are significantly reduced in STI-A1010 group

  21. Slide 21: Potent Antibody against Difficult GPCR Target

    mAb Cell Binding (EC 50 – nM) Days After Disease Induction Sorrento mAb Untreated Potent Antibody against Difficult GPCR Target* Sorrento 0.17 Competitor * Sorrento mAb against C-C Chemokine Receptor 2 (CCR2) ** Experimental Auto-immune Encephalomyelitis (EAE) = murine model of Multiple Sclerosis

  22. Slide 22: Antibody Drug Conjugates (ADCs)

    Antibody Drug Conjugates (ADCs) Key Components: Drug released in CANCER CELL Target-specific internalizing antibody Potent cytotoxic prodrugs Linker and conjugation chemistries 1. 2. 3.

  23. Slide 23: Proprietary High Potency Duostatin Toxins

    Duostatins vs. DM1 Duostatins vs. MMAE Proprietary High Potency Duostatin Toxins Duostatin toxin 1 (K-lock) >15x higher potency Duostatin toxin 2 (K-lock) DM1 (conventional; NHS) Duostatin toxin 1 (K-lock) Duostatin toxin 2 (K-lock) MMAE (conventional; maleimide) SKBR3 (Breast Cancer Cell Line)

  24. Slide 24: K-Lock Conjugation Enables Homogeneous ADCs

    purified K-Lock Conjugation Enables Homogeneous ADCs Current industry standard chemistry Proprietary K-Lock chemistry Sorrento’s homogenous ADC No need for: non-natural amino acids genetic re-engineering enzymatic posttranslational modification

  25. Slide 25: C-Lock Conjugation Stabilizes ADCs

    C-Lock Conjugation Stabilizes ADCs C-lock conjugation Enhances ADC stability Prolongs PK profile Reduced off-target effects Current industry standard Maleimide conjugation Destabilizes antibody structure Reduced target specificity Altered PK profile Drug-antibody linkage not stable Off-target drug e

  26. Slide 26: Proprietary ADC Screening and Optimization Panels

    Proprietary ADC Screening and Optimization Panels Fast track to IND Identification of optimal combination of linker, conjugation chemistry and drug payload essential for efficient and expedited development from target to candidates

  27. Slide 27: Company Comparables

    Sorrento: SRNE ~$330M Company Comparables Company Small Molecule Oncology Drug Antibody Platform Targeted Drug Delivery Mkt Cap* Puma: Pre-revenue MBC (Phase 3) ~$3.7B Clovis: Pre-revenue NSCLC, MBC (Phase 1) ~$2.9B MorphoSys: Pre-revenue Antibody Library ~$2.5B CAT: Pre-revenue Antibody Library ~$1

  28. Slide 28: Developing Therapeutic Solutions to Help Man's Life Companions

    DEVELOPING THERAPEUTIC SOLUTIONS TO HELP MAN'S LIFE COMPANIONS

  29. Slide 29: Indications for Resiniferatoxin/Vaccine Programs

    VET Indications for Resiniferatoxin/Vaccine Programs Ark-001 (Canine Osteosarcoma) Ark-002 (Canine Osteoarthritis) Ark-004 (Idiopathic Cystitis in cats) Ark-006 (Horse Ocular Pain) Ark-007 (Horse Laminitis) Ark-005 (Mastitis in cows)

  30. Slide 30: Disease-Specific Market Factors: Small Animals

    Disease-Specific Market Factors Small Animals *APPA 2012 and Canine Cancer.com **Veterinary Medicine, Dec 1, 2012 Disease/Drug Unmet Need Competition Prevalence Level of Differentiation Ark-001 (Dogs) Osteosarcoma/Pain High Opiates rare use Amputation Alternative interventions unsatisfactory *83 M P

  31. Slide 31: Disease-Specific Market Factors: Large Animals

    Disease/Drug Unmet Need Competition Prevalence Level of Differentiation Ark-005 (Cows) Mastitis High Antibiotics Mastitis prevention programs Approximately 9.2M cows and 1/3 infected with mastitis annually TBD: Vaccine delivery may offer high differentiation potential Ark-006 (Horses) Ocular Pain/Oc

  32. Slide 32: Market Valuation of Competitor Companies

    Market Valuation of Competitor Companies Products on Market Products in development Disease Area Focus Time to market Market Valuation ARATANA (PETX) None >15 Pain Appetite Stimulants etc Near Term $513 M KINDRED (KIN) None Pain Cancer GI, Allergy Inflammation Autoimmune Near Term $405 M ARK ANIMAL

  33. Slide 33: Sorrento Therapeutics

    Sorrento Therapeutics Next-Generation Cancer Therapeutics Contact: Henry Ji President and CEO [email protected] (858) 668-6923

Sorrento Therapeutics — Investor Presentation (March 2014) on 6ix